BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31515668)

  • 21. SRSF3 and hnRNP H1 regulate a splicing hotspot of HER2 in breast cancer cells.
    Gautrey H; Jackson C; Dittrich AL; Browell D; Lennard T; Tyson-Capper A
    RNA Biol; 2015; 12(10):1139-51. PubMed ID: 26367347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Splicing factor SRSF3 promotes the progression of cervical cancer through regulating DDX5.
    Che Y; Bai M; Lu K; Fu L
    Mol Carcinog; 2023 Feb; 62(2):210-223. PubMed ID: 36282044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thymoquinone Enhances Paclitaxel Anti-Breast Cancer Activity via Inhibiting Tumor-Associated Stem Cells Despite Apparent Mathematical Antagonism.
    Bashmail HA; Alamoudi AA; Noorwali A; Hegazy GA; Ajabnoor GM; Al-Abd AM
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31968657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of TDP43 inhibits progression of triple-negative breast cancer in coordination with SRSF3.
    Ke H; Zhao L; Zhang H; Feng X; Xu H; Hao J; Wang S; Yang Q; Zou L; Su X; Wang L; Wu C; Wang Y; Nie J; Jiao B
    Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3426-E3435. PubMed ID: 29581274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncogenic SRSF3 in health and diseases.
    Jia R; Zheng ZM
    Int J Biol Sci; 2023; 19(10):3057-3076. PubMed ID: 37416784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increase of disintergin metalloprotease 10 (ADAM10) expression in oral squamous cell carcinoma.
    Ko SY; Lin SC; Wong YK; Liu CJ; Chang KW; Liu TY
    Cancer Lett; 2007 Jan; 245(1-2):33-43. PubMed ID: 16309826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncogenic splicing factor SRSF3 regulates ILF3 alternative splicing to promote cancer cell proliferation and transformation.
    Jia R; Ajiro M; Yu L; McCoy P; Zheng ZM
    RNA; 2019 May; 25(5):630-644. PubMed ID: 30796096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kochia scoparia induces apoptosis of oral cancer cells in vitro and in heterotopic tumors.
    Han HY; Lee HE; Kim HJ; Jeong SH; Kim JH; Kim H; Ryu MH
    J Ethnopharmacol; 2016 Nov; 192():431-441. PubMed ID: 27616033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LncRNA HOXA11-AS Promotes Proliferation and Cisplatin Resistance of Oral Squamous Cell Carcinoma by Suppression of miR-214-3p Expression.
    Wang X; Li H; Shi J
    Biomed Res Int; 2019; 2019():8645153. PubMed ID: 31275988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of GDF10/BMP3b as a prognostic marker collaborates with TGFBR3 to enhance chemotherapy resistance and epithelial-mesenchymal transition in oral squamous cell carcinoma.
    Cheng CW; Hsiao JR; Fan CC; Lo YK; Tzen CY; Wu LW; Fang WY; Cheng AJ; Chen CH; Chang IS; Jiang SS; Chang JY; Lee AY
    Mol Carcinog; 2016 May; 55(5):499-513. PubMed ID: 25728212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone.
    Sugimura M; Sagae S; Ishioka S; Nishioka Y; Tsukada K; Kudo R
    Oncology; 2004; 66(1):53-61. PubMed ID: 15031599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma.
    Kioi M; Shimamura T; Nakashima H; Hirota M; Tohnai I; Husain SR; Puri RK
    Int J Cancer; 2009 Mar; 124(6):1440-8. PubMed ID: 19065664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SRSF3/AMOTL1 splicing axis promotes the tumorigenesis of nasopharyngeal carcinoma through regulating the nucleus translocation of YAP1.
    Xu XC; Jiang JX; Zhou YQ; He S; Liu Y; Li YQ; Wei PP; Bei JX; Sun J; Luo CL
    Cell Death Dis; 2023 Aug; 14(8):511. PubMed ID: 37558679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway.
    Zhang W; Cai J; Chen S; Zheng X; Hu S; Dong W; Lu J; Xing J; Dong Y
    Mol Med Rep; 2015 Jul; 12(1):1506-14. PubMed ID: 25760096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
    Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
    Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oxidative stress-inducible truncated serine/arginine-rich splicing factor 3 regulates interleukin-8 production in human colon cancer cells.
    Kano S; Nishida K; Kurebe H; Nishiyama C; Kita K; Akaike Y; Kajita K; Kurokawa K; Masuda K; Kuwano Y; Tanahashi T; Rokutan K
    Am J Physiol Cell Physiol; 2014 Feb; 306(3):C250-62. PubMed ID: 24284797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of growth and angiogenic potential of oral squamous carcinoma cells in vitro using salvianolic acid B.
    Yang Y; Ge PJ; Jiang L; Li FL; Zhu QY
    BMC Complement Altern Med; 2011 Jul; 11():54. PubMed ID: 21726465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
    Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
    Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crocin enhances the sensitivity to paclitaxel in human breast cancer cells by reducing BIRC5 expression.
    Jia Y; Yang H; Yu J; Li Z; Jia G; Ding B
    Chem Biol Drug Des; 2024 Feb; 103(2):e14467. PubMed ID: 38661582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance.
    Su L; Wang Y; Xiao M; Lin Y; Yu L
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct; 110(4):484-91. PubMed ID: 20868995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.